# Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/toripalimab-plus-nab-paclitaxel-in-metastatic-or-recurrent-triple-negative/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Zefei Jiang,Quchang Ouyang,Tao Sun,Qingyuan Zhang,Yuee Teng,Jiuwei Cui,Haibo Wang,Yongmei Yin,Xiaojia Wang,Xin Zhou,Yongsheng Wang,Gang Sun,Jingfen Wang,Lili Zhang,Jin Yang,Jun Qian,Min Yan,Xinlan Liu,Tienan Yi,Ying Cheng,Man Li,Aimin Zang,Shusen Wang,Chuan Wang,Xinhong Wu,Jing Cheng,Hui Li,Ying Lin,Cuizhi Geng,Kangsheng Gu,Chunwei Xie,Huihua Xiong,Xiaohong Wu,Junlan Yang,Qingshan Li,Yiding Chen,Fanfan Li,Anqin Zhang,Yongqiang Zhang,Yudong Wu,Jianyun Nie,Qiang Liu,Kun Wang,Xueli Mo,Lilin Chen,Yueyin Pan,Peifen Fu,Helong Zhang,Danmei Pang,Yuan Sheng,Yunwei Han,Hongxia Wang,Shundong Cang,Xianming Luo,Wenbo Yu,Rong Deng,Chaoqiang Yang,Patricia Keegan |
| Citations | 120 |
| DOI | 10.1038/s41591-023-02677-x |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4390670334 |
| PMID | 38191615 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Yongqiang Zhang](https://scholariq.org/researchers/yongqiang-zhang/)

## Paper journal

- [Nature Medicine](https://scholariq.org/journals/nature-medicine/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.